Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718269 | 0.89 | NR1H2 (0.39) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL17868613 | 0.89 | DDB1 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL21995232 | 0.86 | NR1H2 (0.39) | DDB1CRBNUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL22056023 | 0.86 | NR1H2 (0.39) | DDB1CRBNUSP2SMN1; SMN2NR1H2 | |
| SCHEMBL2123557 | 0.84 | USP2 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL5223609 | 0.84 | USP2 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL17868660 | 0.84 | DDB1 (0.39) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL16221362 | 0.83 | USP2 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL16220613 | 0.83 | USP2 (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 | |
| SCHEMBL173439 | 0.82 | PDE4B (0.41) | DDB1CRBNUSP2SMN1; SMN2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596074-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2022-12-14 | — | — | EP | disclosed |
| EP-3596074-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2022-12-14 | — | — | EP | disclosed |
| CN-110167937-B | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB生物制药私人有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3573986-B1 | BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3573986-B1 | BICYCLIC BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SRL (BE) | 2021-05-26 | — | — | EP | disclosed |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA | 2021-04-06 | — | — | US | disclosed |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA | 2021-04-06 | — | — | US | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | UCB Biopharma SRL (BE) | 2021-01-12 | — | — | US | disclosed |
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2020-11-26 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2086643-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | Glaxo Group Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| EP-1589969-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008053031-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053031-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1589969-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co. Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC1 | DDB1 3943/4885CRBN 3141/4885USP2 3687/4885 |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC1 | DDB1 3943/4885CRBN 3141/4885USP2 3687/4885 |
| US-10889584-B2 | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | PARK7, HTT, SNCA | DDB1 373/4885CRBN 139/4885USP2 476/4885 |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DDB1 644/4885CRBN 4321/4885USP2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.